Nanobiotix (NBTX) announced updates to the JNJ-1900 clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in Q3 of 2024, in the majority of regions along with the transfer of full operational control of the Phase 3 clinical trial to Johnson & Johnson (JNJ). Following the transfer and Nanobiotix analysis of the latest information, Nanobiotix estimates that NANORAY-312 interim data will be analyzed and reported, after both the requisite number of events have been observed and the last patient has been recruited, in 1H2027. Future guidance related to NANORAY-312 and other JNJ-1900-related Johnson & Johnson-sponsored studies will be communicated by Johnson & Johnson. Nanobiotix will continue to provide JNJ-1900 clinical development updates and guidance related to Nanobiotix-sponsored studies as well as studies sponsored by The University of Texas MD Anderson Cancer Center.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix Updates Voting Rights and Share Capital Details
- Nanobiotix SA ADR Reports Revenue Surge Amid Strategic Advances
- Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright
- Nanobiotix Reports Promising Phase 1 Results for Esophageal Cancer Treatment
- Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts